(888) 645-1617

First approved as an antidepressant, Cymbalta also provides pain relief. The drug targets neurochemicals involved in the regulation of both mood and pain.

*Please seek the advice of a medical professional before discontinuing the use of this drug.

Eli Lilly developed Cymbalta as a successor to its highly successful Prozac. Cymbalta became Lilly’s biggest-selling drug at one time, leading a neurosciences division responsible for more than one-fifth of Lilly’s revenues.

Antidepressants had been used to treat pain for years before Cymbalta. But after research in the late 1990s showed Cymbalta could be effective at controlling pain, Lilly pursued opportunities to market it for the treatment of certain types of chronic pain alongside its treatment of depression.

The U.S. Food and Drug Administration (FDA) has approved Cymbalta to treat the following conditions:

  • Major Depressive Disorder
  • Diabetic Peripheral Neuropathy
  • Generalized Anxiety Disorder
  • Fibromyalgia
  • Chronic Musculoskeletal Pain

How Does Cymbalta Treat Pain?

As with depression, no one is quite sure exactly why antidepressants help the body feel relief from pain. But scientists believe the same neurochemicals regulate both pain and mood.

Along with other Serotonin–norepinephrine reuptake inhibitors (SNRIs), Cymbalta, targets levels of serotonin and norepinephrine – two chemicals that are believed to help nerve cells communicate with one another. Scientists believe low levels of these chemicals may cause depression and they also believe the two chemicals — called neurotransmitters — may also affect how a person feels pain.


“There’s some degree of an emotional component to pain. For example, if you're feeling really good, you might not notice your finger's cut. If you're feeling more morose, it's probably going to be bit more of a stronger sensation.”

- Todd Christiansen, Washington, D.C. based child and adolescent psychiatrist


Christiansen said that it doesn’t appear SNRIs affect nerve receptors at the source of the pain, but appear to be affecting the way the brain processes the sensation. This may be in part because of the way Cymbalta interacts with pain messages traveling to and from the brain along the body’s pain pathways.

Pain pathways are categorized as either ascending pathways, those running from the point of pain to the brain, and descending pathways, those running from the brain into the dorsal horn of the spinal cord. The dorsal horn receives certain sensory information from the body.

Brain Stimuli
The brain interpreting Stimuli causing the sensation of pain

For a person to feel pain, the cause of the pain, called stimuli, must send a signal up the ascending pathway. The brain interprets and experiences the pain, but is also able to modulate pain signals. The brain can either amplify or lower the pain signals.

Serotonin and norepinephrine are believed to be involved in lowering the intensity of pain signals on this descending pathway. It is believed Cymbalta’s ability to increase levels of both chemicals allows the brain to better control the pain.

Even if taken to treat pain, patients should not stop Cymbalta suddenly. Doing so can result in serious and sometimes life-threatening withdrawal symptoms. Stopping Cymbalta therapy should only be done under the close supervision of a medical professional.

Cymbalta Approved to Treat Major Depressive Disorder

The FDA first approved Cymbalta to treat major depressive disorder (MDD) on August 4, 2004. MDD is also called clinical depression or just simply depression. It is a persistent feeling of sadness and a loss of interest. It is a common but serious mood disorder and can cause severe symptoms that can affect how a person thinks or feels. It can also interfere with a person’s daily routine, disrupting how a person eats, sleeps or works.

Symptoms of Major Depressive Disorder

There is a lengthy list of symptoms for depression, but not everyone who suffers from depression experiences every symptom. Left untreated, MDD episodes can last between six to 18 months.

The National Institute of Mental Health lists symptoms of depression as:

  • A persistent sad, anxious or “empty” mood
  • Aches or pains, including headaches, cramps or digestive problems without a clear physical cause and that do not ease with treatment
  • Changes in appetite or weight
  • Difficulty concentrating, remembering or making decisions
  • Difficulty sleeping, including waking too early or oversleeping
  • Fatigue or decreased energy
  • Feelings of guilt, helplessness or worthlessness
  • Feelings of hopelessness or pessimism
  • Irritability
  • Loss of interest or pleasure from hobbies and activities, including family life or sex
  • Moving or talking more slowly
  • Restlessness, difficulty sitting still
  • Suicidal thoughts or attempts
  • Thinking about death

Anyone experiencing some of these symptoms most of the day, nearly every day for at least two weeks may be experiencing depression.

How Cymbalta Treats Major Depressive Disorder

The physical mechanics of what causes MDD and the precise mechanism Cymbalta and other SRNIs use to treat it are not fully understood by science. Cymbalta is believed to delay the body’s reabsorption of two neurotransmitters — serotonin and norepinephrine. Neurotransmitters are chemicals which allow nerve cells in the brain to communicate with one another. Scientists believe the extra time the neurotransmitters continue connecting the nerve cells may reduce the effects and symptoms of depression.

Study findings

A pair of studies in 2007 found that while Cymbalta was effective at treating MDD, a sizable percentage of patients taking it reported an adverse event.

Approximately 10 percent of the 1,139 patients with MDD in placebo-controlled trials discontinued treatment due to side effects, compared with 4 percent of the 777 patients receiving placebo, the researchers wrote. “The most common [adverse events] experienced by and more commonly reported by duloxetine than by placebo-treated patients with MDD were nausea, dry mouth, constipation, decreased appetite, fatigue, somnolence, and increased sweating,” the report said.

neurotransitters diagram
It is believed that delaying the exchange of nuerotransmitters can reduce the effects and symptoms of depression

FDA Approves Cymbalta to Treat Diabetic Peripheral Neuropathy

Peripheral neuropathy affects the extremities, including:

  • Toes
  • Feet
  • Legs
  • Hands
  • Arms

On September 7, 2004, just a little over a month after the FDA first approved Cymbalta to treat MDD, the agency approved the drug for the treatment of diabetic peripheral neuropathy — severe pain associated with diabetes. Diabetic peripheral neuropathy may affect up to five million Americans. Cymbalta was the first FDA-approved treatment for the condition.

High blood sugar in people with diabetes can injure nerve fibers throughout the body. Peripheral neuropathy is the most common type of diabetic neuropathy and affects the extremities.

Feet and hands are usually affected before legs and arms. The damage can take years to develop and symptoms may go unnoticed for years.

Symptoms of Diabetic Peripheral Neuropathy

Symptoms can vary depending on which nerves diabetic peripheral neuropathy attacks. Some people may develop the condition without experiencing any symptoms. While many patients may not realize they have symptoms, a doctor may be able to tell.

The National Institutes of Health (NIH) says symptoms can involve sensory, motor and involuntary nervous systems.

The NIH says symptoms of diabetic peripheral neuropathy may include:

  • Blistering on numb parts of the foot
  • Changes in the way a person walks
  • Extreme sensitivity to touch, even light touch
  • Loss of balance and coordination
  • Loss of reflexes, especially at the ankle
  • Muscle weakness
  • Numbness or insensitivity to pain or temperature
  • Onset of foot deformities
  • Sharp pains or cramps
  • Tingling, burning, or prickling sensations

Cymbalta (duloxetine) and the anticonvulsant Lyrica (pregabalin) are FDA approved to treat diabetic peripheral neuropathy.

Depression and weight loss, though not symptoms of the condition, may often accompany diabetic peripheral neuropathy. The fact that Cymbalta might be able to treat both the pain and accompanying depression played a role in Lilly seeking approval for this indication.

How Cymbalta Treats Diabetic Peripheral Neuropathy

As with treating depression, there is no definite explanation about exactly how Cymbalta works to treat diabetic peripheral neuropathy.

It is known that Cymbalta does not repair the nerve damage which leads to diabetic peripheral neuropathy, but studies have shown the drug can relieve the pain and other sensations associated with the condition.

Nuerotransmitters & Cymbalta

Cymbalta increases the levels of the neurotransmitters serotonin and norepinephrine. Scientists believe these two chemicals are responsible for regulating both a person’s mood and their sensitivity to pain.

“Increasing these levels in a balanced way is thought to improve the body’s natural ability to regulate pain,” Eli Lilly said in a statement announcing Cymbalta’s FDA approval to treat diabetic peripheral neuropathy.

Cymbalta Approved to Treat Generalized Anxiety Disorder

In February 2007, the FDA approved Cymbalta for the treatment of generalized anxiety disorder (GAD). In November 2009, the FDA approved Cymbalta for maintenance of GAD.

Fact

Cymbalta carries an FDA “black box” warning about potential suicidal behavior risks.

The FDA approved Cymbalta for treatment of GAD in children and adolescents in 2014. However, doctors must carefully weigh the risks and benefits of prescribing Cymbalta to children, teens and young adults. Cymbalta’s label carries a “black box warning” — the most serious kind from the FDA — warning that use of the drug may lead to an “increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants.”

Generalized anxiety disorder is the constant state of worry about everyday problems — health, finances, relationships and employment — well beyond their proportions for at least six months. It can worsen if the patient faces additional stress or if it persists over time.

GAD affects more than 3 percent of the U.S. adult population and can be serious in almost a third of the people who have it. Fewer than half the people who suffer from generalized anxiety disorder receive treatment.

It is one of several common anxiety disorders which may share common risk factors. The risk of developing generalized anxiety disorder may increase if a person has certain genetic or environmental factors.

The National Institute for Mental Health says these may include:

  • Anxiety disorders in close biological relatives
  • Being divorced or widowed
  • Being female
  • Exposure to stressful life events in childhood and adulthood
  • Having few economic resources
  • Parental history of mental disorders
  • Shyness, or behavioral inhibition, in childhood

Several treatment options may be indicated for generalized anxiety disorder including psychotherapy, support groups, stress-management and medication. Medicines such as Cymbalta cannot cure anxiety disorders but they can relieve symptoms.

Symptoms of Generalized Anxiety Disorder

Generalized anxiety disorder is a form of anxiety that can persist for months and simply not go away.

According to the National Institute of Mental Health, symptoms of GAD include:

  • Being easily fatigued
  • Difficulty concentrating
  • Difficulty controlling worries
  • Feeling wound-up, on edge
  • Irritability
  • Restlessness
  • Sleep problems (difficulty falling asleep, staying asleep)

People with GAD may experience physical symptoms, such as gastrointestinal issues or muscle tension in addition to, or even instead of, mental worries. In addition, people at greater risk of GAD tend to be unsure of themselves, more likely to conform and perfectionists.

How Cymbalta Treats Generalized Anxiety Disorder

In 2007, two studies of a total of 840 patients with GAD found those who took Cymbalta experienced greater ability to perform everyday activities at home, work and in social situations compared to those who took a placebo.

More than a third of the improvement in function was due to what researchers called “an undefined effect of Cymbalta.” Researchers believe the effect Cymbalta plays on increasing levels of serotonin and noradrenaline, and inhibiting their reabsorption, plays a role in the drug’s ability to relieve GAD symptoms.

A 2009 study found that the pain-relieving benefits of Cymbalta may also benefit those generalized anxiety disorder (GAD) patients who suffer physical pain as part of their symptoms.

“Given that GAD patients with pain have more severe symptoms, this analysis shows that duloxetine (Cymbalta) can deliver significant reductions in pain in patients with anxiety,” the researchers wrote.

FDA Approves Cymbalta to Treat Fibromyalgia

Fact

Cymbalta is one of only three drugs approved to treat fibromyalgia pain.

In June 2008, the FDA approved Cymbalta for the management of fibromyalgia — a chronic, widespread pain disorder.

Fibromyalgia is characterized by pain and tenderness throughout the body in a way that reduces a person’s ability to function or affects their overall quality of life. Between 1 and 5 percent of U.S. adults have fibromyalgia with women being far more likely than men to develop it. As much as 90 percent of people with fibromyalgia are women.

Most cases develop in people between the ages of 40 and 70.

Duloxetine, the active ingredient in Cymbalta, is one of three drugs approved by the FDA to treat fibromyalgia. The other two are pregabalin (Lyrica) and milnacipran (Savella).

Symptoms of Fibromyalgia

In addition to pain, the symptoms of fibromyalgia may include:

  • Cognitive and memory problems (“fibro fog”)
  • Trouble sleeping
  • Morning stiffness
  • Headaches
  • Irritable bowel syndrome
  • Painful menstrual periods
  • Numbness or tingling of hands and feet
  • Sensitivity to temperature, loud noises or bright lights

People with rheumatoid arthritis, lupus, and spinal arthritis may be more likely to develop fibromyalgia.

But coming off Cymbalta for treatment of fibromyalgia may result in problems. Fibromyalgia patients attending a 2014 FDA public hearing on drug development for fibromyalgia discussed their experiences.

“All of the prescription medications for fibromyalgia have not helped me in any way, in fact, coming off of Cymbalta, even though I tittered off of it, threw me into one of the worst flare-ups that I’ve ever had,” patient Laura Dugan told the FDA.

“I found the FDA approved drugs, Lyrica and Cymbalta, caused more problems and didn’t alleviate the pain,” another fibromyalgia sufferer, Nancy Ryan, testified. “I had a bad reaction to Cymbalta.”

How Cymbalta Treats Fibromyalgia

Cymbalta may relieve some, but not all symptoms of fibromyalgia. It can ease pain, address sleep issues and depression associated with the condition. But it doesn’t address the other symptoms.

The cause of fibromyalgia is not known, but some researchers believe it may be related to a problem in the nervous system. It may result from a previous injury, emotional stress or viruses that change the way the brain perceives pain. Nerves may continue to fire despite the lack of a physical injury, causing a person to feel pain when others normally would not.

Serotonin and norepinephrine are believed to lessen the painful effects of fibromyalgia on nerve fibers. Cymbalta’s ability to raise levels of serotonin and norepinephrine is believed to relieve the symptoms of fibromyalgia. Depression can also accompany fibromyalgia, and Cymbalta’s antidepressant qualities.

Cymbalta Approved to Treat Chronic Musculoskeletal Pain

In November 2010, the FDA approved Cymbalta for the treatment of musculoskeletal pain. Musculoskeletal refers to the combined workings of the body’s skeleton and muscles.

FDA Approval

The FDA approved Cymbalta after clinical trials involving patients with osteoarthritis or chronic lower back pain.

Musculoskeletal pain is one of the most common types of pain with about 75 percent of Americans experiencing it at some point in their lifetime. Osteoarthritis and lower back pain account for the majority of chronic cases, defined as a pain that lasts longer than three months, typically outlasting a normal healing process for an injury.

In approving Cymbalta for chronic musculoskeletal pain, the FDA acknowledged Cymbalta’s link to serious side effects including suicide, suicidal thoughts and behavior, liver damage and pneumonia. But the agency said there were few other drugs as effective in treating musculoskeletal pain.

“While these serious side effects have been associated with the use of Cymbalta, they have occurred in less than 1% of treated patients,” the FDA said in a statement. “There are a finite number of drugs available for the treatment of chronic musculoskeletal pain, all of which are associated with rare, serious side effects. There are patients in whom none of the available treatments are effective.”

Osteoarthritis diagram
Osteoarthritis accounts for the majority of chronic cases

Symptoms of Chronic Musculoskeletal Pain

Musculoskeletal pain may be the result of an injury to the bones, joints, muscles, tendons, ligaments or nerves in the body. It can be caused by falls, broken bones, dislocated or sprained joints, or direct impact with muscles.

Symptoms of musculoskeletal pain may include:

  • Aching or stiffness of the entire body
  • Any pain that worsens with movement
  • Burning sensation in the muscles
  • Difficulty sleeping
  • Fatigue
  • Sensation of pulled or overworked muscles
  • Twitching muscles

How Cymbalta Treats Chronic Musculoskeletal Pain

Fact

An FDA advisory committee voted against approving Cymbalta to treat osteoarthritis pain.

Again, researchers remain uncertain about exactly how Cymbalta eases arthritis, lower back pain and other chronic musculoskeletal pain. It is believed again, that Cymbalta raises serotonin and norepinephrine levels, in turn affecting the way the brain processes pain by inhibiting certain pain pathways in the central nervous system.

FDA studies showed that while Cymbalta was “noninferior” to other drugs for treating arthritis, it was not superior to any other prescription treatment options already available.

The FDA’s Anesthetic and Life Support Drugs advisory committee was split in its opinions over Cymbalta as an arthritis medicine. It voted 9-4 against approving the drug to treat osteoarthritis, even though the agency later approved Cymbalta for treating the condition.

Author

Terry Turner is an Emmy-winning, former television journalist. As a Washington-based reporter for a group of 100 local news departments across the U.S., he routinely reported on health and medical policy issues before Congress, the FDA and other federal agencies. Prior to that, he covered state and federal courts for several local television stations in the Midwest and on the East Coast.


Hide Sources

  1. Edmonds, M. (2009, March 19). Cymbalta: What You Need to Know. Retrieved from: http://health.howstuffworks.com/medicine/medication/cymbalta.htm
  2. Fawcett, K. (2014, November 5). 6 Little-Known Uses for Antidepressants. Retrieved from: http://health.usnews.com/health-news/patient-advice/articles/2014/11/05/6-little-known-uses-for-antidepressants
  3. National Institutes of Health. (2016, October). Depression. Retrieved from: https://www.nimh.nih.gov/health/topics/depression/index.shtml
  4. Goldstein, D.J. (2007, April). Duloxetine in the Treatment of Major Depressive Disorder. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654630/
  5. NIH. (2013, November). Nerve Damage (Diabetic Neuropathies). Retrieved from: https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies
  6. Eli Lilly. (2004, September). FDA Approves Antidepressant Cymbalta for Treatment of Pain Caused by Diabetic Peripheral Neuropathy, Which Affects up to 5 Million Americans. Retrieved from: https://investor.lilly.com/releasedetail2.cfm?releaseid=148686
  7. National Institute of Mental Health. (n.d.). Generalized Anxiety Disorder Among Adults. Retrieved from: https://www.nimh.nih.gov/health/statistics/prevalence/generalized-anxiety-disorder-among-adults.shtml
  8. National Institute of Mental Health. (2016, March). Anxiety Disorders. Retrieved from: https://www.nimh.nih.gov/health/topics/anxiety-disorders/index.shtml
  9. University of Maryland Medical Center. (2013, March 11). Anxiety Disorders. Retrieved from: http://www.umm.edu/health/medical/reports/articles/anxiety-disorders
  10. Norman, T.R. and Oliver, J.S. (2008, December). Duloxetine in the Treatment of Generalized Anxiety Disorder. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646646/
  11. Wright, A. and VanDenBerg, C. (2009, December 29). Duloxetine in the Treatment of Generalized Anxiety Disorder. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840566/
  12. FDA. (2017). Cymbalta Label. Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021427s049lbl.pdf
  13. Consumer Reports. (2014). Evaluating Prescription Drugs Used to Treat Fibromyalgia. Retrieved from: http://article.images.consumerreports.org/prod/content/dam/cro/news_articles/health/PDFs/Fibromyalgia_full_report.pdf
  14. U.S. Office on Women’s Health. (2017, June 12). Fibromyalgia. Retrieved from: https://www.womenshealth.gov/a-z-topics/fibromyalgia
  15. FDA. (2014, March 26). Fibromyalgia Public Meeting Patient-Focused Drug Development. Retrieved from: https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm393377.pdf
  16. Smith, H.S., Smith, E.J. and Smith, B.R. (2012, June 19). Duloxetine in the Management of Chronic Musculoskeletal Pain. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387831/
  17. Brown, J.P. and Boulay, L.J. (2013, December). Clinical Experience with Duloxetine in the Management of Chronic Musculoskeletal Pain. A Focus on Osteoarthritis of the Knee. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836379/
  18. Eli Lilly. (2010, November 4). FDA Approves Cymbalta for Management of Chronic Musculoskeletal Pain. Retrieved from: https://investor.lilly.com/releasedetail.cfm?releaseid=527460